Axsome Therapeutics

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axsome Therapeutics reports robust Q4 performance and eyes global expansion

Axsome Therapeutics had a strong Q4 2022, driven by successful commercialization of Auvelity and Sunosi.
While facing challenges such as legal disputes and payer coverage, the company is well-positioned for growth.
Strategic opportunities in expanding product portfolio and market access present avenues for future success.
Financially stable with a focus on innovation, Axsome is poised for continued growth and market expansion.

Axsome Therapeutics excels in Q1 2023 despite financial hurdles

Axsome Therapeutics demonstrated strong commercial and pipeline progress in Q1 2023, despite financial challenges.
The company's focus on expanding market share and optimizing commercial operations bodes well for future growth.
While facing challenges in sales guidance and NDA filings, Axsome's strong financial position and product performance offer opportunities for sustained success.

Axsome Therapeutics reports robust Q2 sales and expands product portfolio

Axsome Therapeutics demonstrated strong sales performance driven by Auvelity and Sunosi, with a focus on future growth potential.
Despite challenges such as increased costs and a net loss, the company is strategically expanding its product portfolio and market reach.
Opportunities lie in new FDA indications for existing products and the goal to have five marketed products by 2025.

Axsome Therapeutics reports robust Q3 earnings and outlines growth strategies

Axsome Therapeutics delivered strong revenue growth in Q3 2023, driven by Auvelity and Sunosi, showcasing a promising commercial outlook.
The company's pipeline progress and upcoming milestones reflect a commitment to innovation and expansion in the CNS therapeutic space.
While challenges like ongoing losses and strategic resource allocation persist, opportunities in new markets and product diversification offer avenues for future growth.

Axsome Therapeutics reports robust 2023 performance and eyes growth opportunities

Axsome Therapeutics had a strong financial performance in 2023, driven by the success of Auvelity and Sunosi. Despite challenges like increased expenses and net loss, opportunities for growth exist through new indications and expanded payer coverage.

Axsome Therapeutics excels in Q1 2024, poised for growth

Axsome Therapeutics demonstrated exceptional financial growth and pipeline advancements in Q1 2024, particularly in neuroscience programs like AXS-12.
Strong commercial performance of Auvelity and Sunosi, coupled with stable payer coverage and growth strategies, underpin the company's success trajectory.
While facing challenges related to study timelines and cybersecurity, Axsome Therapeutics remains poised to capitalize on upcoming milestones and market opportunities.

Axsome Therapeutics excels in Q2 2024, eyes market expansion

Axsome Therapeutics delivered a strong performance in Q2 2024, driven by revenue growth and progress on key product developments.
While facing challenges in market competition and operational execution, the company remains optimistic about future prospects.
Strategic opportunities in market expansion and product innovation position Axsome well for sustained growth and success in the CNS treatment space.

Axsome Therapeutics excels in Q3 with record revenue and pipeline progress

Axsome Therapeutics delivered a strong performance in Q3 2024, surpassing $100 million in quarterly product revenue and maintaining a solid financial position.
The company's strengths lie in its successful products, robust pipeline, and strategic commercial initiatives, supported by a strong cash reserve.
Challenges include managing expenses, navigating market dynamics, and sustaining commercial momentum, while opportunities exist in product launches and market expansion.
Overall, Axsome's performance reflects a balanced approach to growth, innovation, and market competitiveness, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Johnson & Johnson

Novavax

Take a look at a few trending biotech stocks and decide if this is something you want to invest in.

Are Biotech Stocks a Good Idea Right Now?

Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.

Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options

Axsome (AXSM) posts favorable data from the long-term phase III study evaluating AXS-07 for acute treatment of migraine. The company also begins a second phase III study on AXS-05 for AD agitation.

Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study

ACCORD is the second pivotal trial of AXS-05 in Alzheimer's disease agitation

Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer's Disease Agitation

 Over 21,000 migraine attacks treated with AXS-07

Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine

The second half of 2020 has been pretty dull in terms of AXSM trading relative to the first half. Several positive readouts in H2'20 provided only a modest boost but set the stage for a H1'21 readout of MERIT, a placebo controlled study of AXS-05 in treatment-resistant depression.

Several High Impact Catalysts For Axsome In H1 2021

68 % reduction in MADRS Suicidality Item score by Week 1, and 82% reduction by Week 4

Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Why Is Axsome (AXSM) Up 15.2% Since Last Earnings Report?

R apid and substantial i mprovement in depressive symptoms achieved by 44 % of patients at 2 weeks, 67 % at 6 weeks (MADRS response) , and sustained with long-term treatment

Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression

R apid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response) , and sustained over 12 months

Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder

Axsome (AXSM) earnings meet estimates in the third quarter. The company stretches the timeline for the NDA filing for AXS-05 and AXS-07.

Axsome's (AXSM) Q3 Earnings In Line, Pipeline Progresses

Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q3 2020 Results - Earnings Call Transcript

Veeva Systems

NEW YORK & PLEASANTON, Calif.--(BUSINESS WIRE)-- #digitalengagement--Axsome and Veeva announced a strategic partnership to augment the build of Axsome's Digital-Centric Commercialization (DCC™) platform.

Axsome Therapeutics and Veeva Systems Partner to Build Axsome's Digital-Centric Commercialization™ Platform

NEW YORK, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will present data from the ADVANCE-1 trial of AXS-05 in Alzheimer's disease agitation in an oral session at the 13th Clinical Trials on Alzheimer's Disease (CTAD) conference, to be held digitally, November 4-7. AXS-05 (dextromethorphan/bupropion modulated delivery tablet) is a novel, oral, NMDA receptor antagonist with multimodal activity.

Axsome Therapeutics to Present Data from the ADVANCE-1 Trial of AXS-05 in Alzheimer's Disease Agitation at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Axsome to host conference call and webcast on Thursday, November 5, 2020 at 8:00 AM Eastern Time

Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020

Axsome has an excellent pipeline of late stage CNS candidates. The total market opportunity of all 4 assets is nearly $8bn.

Axsome Therapeutics: An Excellent Pipeline Of Approvable CNS Products

Madrigal Pharmaceuticals

Nikola

Tilray Brands

When it comes to extreme wealth creation, few endeavors can compare to being an owner of a small-cap stock that grows large. The post Small-Cap Stocks Have Led Every Bull Market for Decades appeared first on InvestorPlace.

Small-Cap Stocks Have Led Every Bull Market for Decades

The Recent Sell-Off In Axsome Creates A Good Opportunity

Today, we revisit Axsome Therapeutics for an in-depth analysis.

The Play On Axsome Therapeutics

Non-dilutive  committed capital  extends cash runway into at least 2024

Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital

        S ignificantly faster  time to  pain relief as compared to rizatriptan  (p

Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Demonstrating Rapid Onset of Action and Reduced Symptom Recurrence in the Acute Treatment of Migraine

Axsome (AXSM) accelerates the development plan for AXS-12 to treat narcolepsy after a Breakthrough Therapy meeting with the FDA authorities. Stock dips.

Axsome Expedites Development Plan for Narcolepsy Candidate

Axsome Reports Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma

Single Phase 3 trial  to be conducted  to support  an  NDA filing of AXS-12 in the treatment of narcolepsy;  trial  initiation anticipated 1Q 2021

Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting

Data from MOMENTUM Phase 3 trial to be presented at the 2020 AAN Science Highlights Platform

Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the American Academy of Neurology Science Committee as Featured Presentation

News for Axsome Therapeutics Stock (AXSM)